APR 13 2026
Travere Therapeutics — Filspari (sparsentan) $TVTX
for focal segmental glomerulosclerosis
FDA approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis.
About
Focal segmental glomerulosclerosis (FSGS) is a kidney disease where scarring damages the filters that keep protein from leaking into urine, often leading to swelling and eventual kidney failure. Sparsentan blocks two key receptors (endothelin and angiotensin) that drive inflammation and scarring in kidney tissue. By simultaneously calming both pathways, Filspari may slow the protein loss that pushes FSGS patients toward dialysis.
Pivotal trial
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Filspari
- Why Travere Therapeutics (TVTX) Is Up 6.2% After New FILSPARI IgA Nephropathy Patent Protection - simplywall.st
- A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037 - Sahm
- A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037 - simplywall.st
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - Business Wire
- Travere receives patent allowance for Filspari IgA nephropathy use - Investing.com